Analyze Diet
Journal of equine science2022; 33(3); 51-54; doi: 10.1294/jes.33.51

Concentration of cephalothin in body fluids and tissue samples of Thoroughbred horses.

Abstract: Cephalothin (CET) concentrations in body fluids (plasma, synovial fluid, pleural fluid, peritoneal fluid, and aqueous humor) and tissue samples (bone, lung, jejunum, hoof, and subcutaneous tissue) were investigated to consider the treatment of infectious diseases in horses. CET 22 mg/kg body weight was intravenously administered to 12 horses. Samples were collected from four different horses at 1, 3, and 5 hr after administration. The CET concentration in body fluids other than aqueous humor was maintained above the MIC90 values of Streptococcus zooepidemicus and Staphylococcus aureus until 5 hr, but it was not maintained above that of S. aureus in bone. CET (22 mg/kg twice a day) is effective for septic arthritis, pleuritis, and peritonitis caused by gram-positive bacteria but ineffective for osteomyelitis.
Publication Date: 2022-09-21 PubMed ID: 36196140PubMed Central: PMC9522621DOI: 10.1294/jes.33.51Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article investigates the concentration of cephalothin (an antibiotic) in various body fluids and tissues of horses to determine its effectiveness in treating infectious diseases. It specifically examines how long the drug stays effective against common pathogens found in horses.

Study Design and Procedure

  • The study was conducted on 12 Thoroughbred horses. The selection of the horse breed was not mentioned, but Thoroughbreds were likely chosen due to common use in veterinary research, their susceptibility to certain diseases, or their size (making sample collection easier).
  • Cephalothin was given to the horses via intravenous administration at a dosage of 22 mg/kg body weight. This method ensured that the drug was rapidly distributed throughout the body.
  • Samples of various body fluids (like plasma, synovial fluid, etc.) and tissues (like bone, lung, etc.) were collected from four different horses at different time intervals post-administration: 1 hour, 3 hours, and 5 hours. The differing time intervals were chosen to observe the maintenance of the drug concentration over time.

Results and Implications

  • The results indicated that, aside from in the aqueous humor (fluid in the eye), the concentration of cephalothin was maintained above the Minimum Inhibitory Concentration (MIC) values of Streptococcus zooepidemicus and Staphylococcus aureus up to 5 hours post-treatment. This suggests that cephalothin remains effective in treating infections from these bacteria in most body fluids for a considerable duration after being administered.
  • However, the cephalothin concentration in bone tissue did not remain above the MIC for S. aureus past the 5-hour mark. This means the drug might not be efficient in treating osteomyelitis (bone infection) caused by this particular bacterium.
  • The study suggests that a dose of 22 mg/kg of cephalothin given twice a day could be effective for treating septic arthritis, pleuritis (lung tissue inflammation), and peritonitis (inflammation of the peritoneum) caused by gram-positive bacteria in horses. However, further investigations need to be done to substantiate these findings and to judge the drug’s long-term effectiveness.

General Context and Conclusion

  • Many infections in horses are caused by the gram-positive bacteria Streptococcus zooepidemicus and Staphylococcus aureus, ergo understanding the effectiveness of a particular antibiotic like cephalothin against these pathogens is valuable for veterinary medicine.
  • The study concludes by stressing that, while cephalothin can be an effective treatment for several infections caused by these bacteria in horses, it may not be suitable for treating bone infections (osteomyelitis). This conclusion was based on the observation that the cephalothin levels in bone tissue did not remain high enough for enough time to combat S. aureus sufficiently.

Cite This Article

APA
Kuroda T, Minamijima Y, Niwa H, Mita H, Tamura N, Fukuda K, Kuwano A, Sato F. (2022). Concentration of cephalothin in body fluids and tissue samples of Thoroughbred horses. J Equine Sci, 33(3), 51-54. https://doi.org/10.1294/jes.33.51

Publication

ISSN: 1340-3516
NlmUniqueID: 9503751
Country: Japan
Language: English
Volume: 33
Issue: 3
Pages: 51-54

Researcher Affiliations

Kuroda, Taisuke
  • Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Tochigi 329-0412, Japan.
Minamijima, Yohei
  • Laboratory of Racing Chemistry, Tochigi 320-0851, Japan.
Niwa, Hidekazu
  • Microbiology Division, Equine Research Institute, Japan Racing Association, Tochigi 329-0412, Japan.
Mita, Hiroshi
  • Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Tochigi 329-0412, Japan.
Tamura, Norihisa
  • Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Tochigi 329-0412, Japan.
Fukuda, Kentaro
  • Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Tochigi 329-0412, Japan.
Kuwano, Atsutoshi
  • Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Tochigi 329-0412, Japan.
Sato, Fumio
  • Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Tochigi 329-0412, Japan.

References

This article includes 19 references
  1. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., Drusano G.L.. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore.. Clin. Infect. Dis. 44: 79–86.
    pubmed: 17143821
  2. Arnold C., Pilla R., Chaffin K., Lidbury J., Steiner J., Suchodolski J.. Alterations in the fecal microbiome and metabolome of horses with antimicrobial-associated diarrhea compared to antibiotic-treated and non-treated healthy case controls.. Animals (Basel) 11: 1807.
    pmc: PMC8235368pubmed: 34204371
  3. Corser C.A., Day G.J., Humble M.W.. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.. N. Z. Med. J. 95: 414–416.
    pubmed: 6810246
  4. Cox K.S., Nelson B.B., Wittenburg L., Gold J.R.. Plasma, subcutaneous tissue and bone concentrations of ceftiofur sodium after regional limb perfusion in horses.. Equine Vet. J. 49: 341–344.
    pubmed: 27458113
  5. Davis J.L.. Pharmacologic principal.. pp. 103. In: Equine Internal Medicine, 4th ed. (Reed, S.M., Bayly, W.M. and Sellon, D.C. eds.), Saunders, Pennsylvania..
  6. Fjordbakk C.T., Arroyo L.G., Hewson J.. Retrospective study of the clinical features of limb cellulitis in 63 horses.. Vet. Rec. 162: 233–236.
    pubmed: 18296664
  7. González-Martín M., Silva V., Poeta P., Corbera J.A., Tejedor-Junco M.T.. Microbiological aspects of osteomyelitis in veterinary medicine: drawing parallels to the infection in human medicine.. Vet. Q. 42: 1–11.
    pmc: PMC8725753pubmed: 34936853
  8. Kavanagh N., Ryan E.J., Widaa A., Sexton G., Fennell J., O’Rourke S., Cahill K.C., Kearney C.J., O’Brien F.J., Kerrigan S.W.. Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions.. Clin. Microbiol. Rev. 31: e00084-17.
    pmc: PMC5967688pubmed: 29444953
  9. Kuroda T., Minamijima Y., Niwa H., Tamura N., Mita H., Fukuda K., Kaimachi M., Suzuki Y., Enoki Y., Taguchi K., Matsumoto K., Toutain P.L., Bousquet-Melou A., Kasashima Y.. Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses.. Equine Vet. J. 53: 1239–1249.
    pmc: PMC8518962pubmed: 33341979
  10. Matsuda Y., Hobo S., Naito H.. Transferability of cephalothin to the alveolar cavity in thoroughbreds.. J. Vet. Med. Sci. 61: 209–212.
    pubmed: 10331190
  11. Nomura M., Kuroda T., Tamura N., Muranaka M., Niwa H.. Mortality, clinical findings, predisposing factors and treatment of Clostridioides difficile colitis in Japanese thoroughbred racehorses.. Vet. Rec. 187: e14.
    pubmed: 32201380
  12. Onufrak N.J., Forrest A., Gonzalez D.. Pharmacokinetic and pharmacodynamic principles of anti-infective dosing.. Clin. Ther. 38: 1930–1947.
    pmc: PMC5039113pubmed: 27449411
  13. Otagiri M.. [Study on binding of drug to serum protein].. Yakugaku Zasshi 129: 413–425[Article in Japanese].
    pubmed: 19336995
  14. Richardson D.W., Stewart S.. Synovial and osseous infection.. pp. 1458–68. In: Equine surgery, 5th ed. (Jörg, A.A., John, A.S., Jan, M.K. and Timo, P. eds.), Elsevier, St. Louis..
  15. Rubio-Martínez L., López-Sanromán J., Cruz A.M., Santos M., San Román F.. Medullary plasma pharmacokinetics of vancomycin after intravenous and intraosseous perfusion of the proximal phalanx in horses.. Vet. Surg. 34: 618–624.
    pubmed: 16343150
  16. Ruoff W.W., Jr, Sams R.A.. Pharmacokinetics and bioavailability of cephalothin in horse mares.. Am. J. Vet. Res. 46: 2085–2090.
    pubmed: 4062011
  17. Thabit A.K., Fatani D.F., Bamakhrama M.S., Barnawi O.A., Basudan L.O., Alhejaili S.F.. Antibiotic penetration into bone and joints: an updated review.. Int. J. Infect. Dis. 81: 128–136.
    pubmed: 30772469
  18. Werner L.A., Hardy J., Bertone A.L.. Bone gentamicin concentration after intra-articular injection or regional intravenous perfusion in the horse.. Vet. Surg. 32: 559–565.
    pubmed: 14648535
  19. Yoshikawa H., Yasu T., Ueki H., Oyamada T., Oishi H., Anzai T., Oikawa M., Yoshikawa T.. Pneumonia in horses induced by intrapulmonary inoculation of Streptococcus equi subsp. zooepidemicus.. J. Vet. Med. Sci. 65: 787–792.
    pubmed: 12939505

Citations

This article has been cited 0 times.